The U.S. Trade Representative (USTR) this week released its annual report assessing China’s implementation of its World Trade Organization commitments. Despite China’s commitment four years ago to reduce the time-to-market for innovative drugs, the delays in getting such products to market remain a significant concern. “Another serious ongoing concern stems from China’s proposals in the pharmaceuticals sector that seek to promote government-directed indigenous innovation and technology transfer through the provision of regulatory preferences,” the USTR said. Other drug-related issues raised in the report deal with pricing and patents.

No Comments